ClinicalTrials.gg
CompletedNCT05879081Updated Nov 16, 2026Results posted

Clinical Performance of Masimo MightySat Rx in Pediatric Populations

An interventional study of Masimo MightySat Rx in RRP (Respiration Rate From PPG), sponsored by Masimo Corporation. Completed. Open to participants aged 5 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Masimo Corporation (part of Danaher Corporation) · Interventional and Other

Updated Nov 16, 2026Now CompletedResults posted+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
5 Years to 18 Years
Sex
All
01

Study summary

This is a prospective, non-randomized data collection study to evaluate the clinical performance of the Masimo MightySat Rx in pediatric populations.

02

Conditions studied

  • RRP (Respiration Rate From PPG)
03

In context

Recurrent respiratory papillomatosis

32 studies on the registry are indexed under Recurrent respiratory papillomatosis; 9 are open to participants now.

This study's enrollment of 40 is above the median of 27 across 23 interventional studies indexed under Recurrent respiratory papillomatosis.

Browse Recurrent respiratory papillomatosis studies →

Lead sponsor

Masimo Corporation is the lead sponsor of 106 studies on the registry; 1 is open to participants now.

Of its 79 completed or terminated interventional studies of FDA-regulated products, 67 (85%) have results posted.

First submitted before Masimo Corporation became part of Danaher Corporation.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is 5 to 18 years of age
  • Subject weighs 30 to 50 kg

Exclusion criteria

Exclusion Criteria:

  • Subject has a condition at or around the site of sensor placement or skin abnormalities affecting the sensor placement area such as psoriasis, eczema, angioma, scar tissue, burn, fungal infection, substantial skin breakdown that would prevent monitoring of physiological parameters during the study
  • Subject is unable to sit with minimal movement during data collection.
  • Subject has any medical condition which, in the judgment of the investigator or study staff, renders them ineligible for participation in this study
  • Subject is excluded at the study staff's discretion.
05

Study design

Primary purpose
Other
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    MightySat Rx

    All subjects are enrolled into this arm and will have respiratory measurements obtained.

    Device: Masimo MightySat Rx

Interventions

  • DeviceMasimo MightySat Rx

    Masimo MightySat Rx will be used to measure respiratory values.

06

What researchers measure

Primary outcomes

  1. RRp (Respiration Rate From PPG) Performance of MightySat Rx in Pediatric Populations Meets Its Performance Specifications.

    The outcome measure is the determination of MightySat Rx performance by calculating the Mean Error and ARMS value through the comparison of RRp obtained by MightySat Rx against the reference (RRref) based on capnography. Mean Error = (∑(i=1 to n) ((RRP\_i-RRref\_i ))/n. Arms= √(∑(i=1 to n) ((RRP\_i-RRref\_i )\^2 ))/n.

    Time frame: Approximately 15 minutes

07

Results

Posted Nov 16, 2026

Participant flow

Participant flow — Overall Study
MilestoneMightySat Rx
Started40
Completed40
Not completed0

Outcome measures

PrimaryRRp (Respiration Rate From PPG) Performance of MightySat Rx in Pediatric Populations Meets Its Performance Specifications.

The outcome measure is the determination of MightySat Rx performance by calculating the Mean Error and ARMS value through the comparison of RRp obtained by MightySat Rx against the reference (RRref) based on capnography. Mean Error = (∑(i=1 to n) ((RRP\_i-RRref\_i ))/n. Arms= √(∑(i=1 to n) ((RRP\_i-RRref\_i )\^2 ))/n.

Time frame:
Approximately 15 minutes
Reported as:
Number · RPM (Respirations per minute)
RRp (Respiration Rate From PPG) Performance of MightySat Rx in Pediatric Populations Meets Its Performance Specifications.
RPM (Respirations per minute)MightySat Rx
Mean Error-0.51
ARMS2.08

Adverse events

Collected over Approximately 15 minutes. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MightySat Rx0/40 (0%)0/40 (0%)0/40 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)MightySat Rx
<=18 years40
Between 18 and 65 years0
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)MightySat Rx
Female22
Male18
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MightySat Rx
American Indian or Alaska Native0
Asian5
Native Hawaiian or Other Pacific Islander1
Black or African American7
White27
More than one race0
Unknown or Not Reported0
08

Study locations

No study locations are listed for this record.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Jul 2023, 2 months.

Results were first posted in Nov 2026, 3 years 4 months after primary completion. A results delay was requested in Aug 2024.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2023
First posted
May 30, 2023
StartActual
May 4, 2023
Primary completionActual
Jul 10, 2023
CompletionActual
Jul 10, 2023
Results delay requested
Aug 19, 2024
Results first posted
Nov 16, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Withheld→Completed
changed Nov 16, 2026
Results
Results posted
posted Nov 16, 2026
Start date
Set to May 4, 2023 (actual)
Nov 16, 2026
Primary completion
Set to Jul 10, 2023 (actual)
Nov 16, 2026
Study completion
Set to Jul 10, 2023 (actual)
Nov 16, 2026
Eligibility
Revised
Nov 16, 2026
Interventions
Arms or interventions changed
Nov 16, 2026
Documents
Title
[Trial of device that is not approved or cleared by the U.S. FDA]→Clinical Performance of Masimo MightySat Rx in Pediatric Populations
Nov 16, 2026
Sponsor
[Redacted]→Masimo Corporation
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Withheld→Completed
    Results posted
    Start date Set to May 4, 2023 (now actual)
    Primary completion Set to Jul 10, 2023 (now actual)
    Study completion Set to Jul 10, 2023 (now actual)
    Eligibility Revised
    Interventions Arms or interventions changed
    Sponsor [Redacted]→Masimo Corporation
    Title [Trial of device that is not approved or cleared by the U.S. FDA]→Clinical Performance of Masimo MightySat Rx in Pediatric Populations
    + 9 other changes: registry dates, verification date, oversight details, description, conditions, design details, secondary outcomes, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05879081
Lead sponsor
Masimo Corporation
Responsible party
Sponsor
First posted
May 30, 2023
Start date
May 4, 2023
Primary completion
Jul 10, 2023
Completion
Jul 10, 2023
Results posted
Nov 16, 2026
Last update
Nov 16, 2026

Oversight

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion